Helga Caputo Nunes

Helga Caputo Nunes

Auto-generated profile, based on publicly available information

Helga Caputo Nunes

Brazilian Center for Research in Energy and Materials

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2022 in Environmental Toxicology
Verified
Journal Article
Closed access
HNHelga Caputo Nunes
Helga Caputo Nunes
STSamara Costa Tavares
Samara Costa Tavares
HGHeloísa Vicente Garcia
Heloísa Vicente Garcia
MCMaira Cucielo
Maira Cucielo
SSSergio Alexandre Alcantara Dos Santos
Sergio Alexandre Alcantara Dos Santos
FDFlavia Karina Delella
Flavia Karina Delella

23 December 2021 in Medicine
Verified
Journal Article
Open access
MBMatheus Bertanha
Matheus Bertanha
LRLenize da Silva Rodrigues
Lenize da Silva Rodrigues
PFPedro Luciano Mellucci Filho
Pedro Luciano Mellucci Filho
AMAndrei Moroz
Andrei Moroz
MPMaria Inês de Moura Pardini
Maria Inês de Moura Pardini
CFCarlos Magno Castelo Branco Fortaleza
Carlos Magno Castelo Branco Fortaleza
Background: Coronavirus disease 2019 (COVID-19) is a viral respiratory disease that spreads rapidly, reaching pandemic status, causing the collapse of numerous health systems, and a strong economic and social impact. The treatment so far has not been well established and there are several clinical trials testing known drugs that have antiviral activity, due to the urgency that the global situation imposes. Drugs with specific mechanisms of action can take years to be discovered, while vaccines may also take a long time to be widely distributed while new virus variants emerge. Thus, drug repositioning has been shown to be a good strategy for defining new therapeutic approaches. Studies of the effect of enriched heparin in the replication of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) in vitro assays justify the advance for clinical tests. Methods and analysis: A phase I/II triple-blind parallel clinical trial will be conducted. Fifty participants with radiological diagnosis of grade IIA pneumonia will be selected, which will be allocated in 2 arms. Participants allocated in Group 1 (placebo) will receive nebulized 0.9% saline. Participants allocated in Group 2 (intervention) will receive nebulized enriched heparin (2.5 mg/mL 0.9% saline). Both groups will receive the respective solutions on a 4/4 hour basis, for 7 days. The main outcomes of interest will be safety (absence of serious adverse events) and efficacy (measured by the viral load). Protocols will be filled on a daily basis, ranging from day 0 (diagnosis) until day 8.

1 June 2019 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
FMFlavio Henrique Mendes
Flavio Henrique Mendes
FVFausto Viterbo
Fausto Viterbo
EDElenice Deffunne
Elenice Deffunne
MDMaria Aparecida Custódio Domingues
Maria Aparecida Custódio Domingues
MGMarjorie de Assis Golim
Marjorie de Assis Golim
HNHelga Caputo Nunes
Helga Caputo Nunes

31 August 2026 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
LFLuiz Henrique de Freitas Filho
Luiz Henrique de Freitas Filho
CNCristina de Carvalho Silva Neves
Cristina de Carvalho Silva Neves
GMGustavo Bregalda Mattos
Gustavo Bregalda Mattos
PRPetrus de Paula Ribeiro
Petrus de Paula Ribeiro
HHHelga Caputo Nunes Holzhausen
Helga Caputo Nunes Holzhausen
GCGustavo Constantino de Campos
Gustavo Constantino de Campos
Introduction: Regulations governing good practices in Human Tissue Banks (HTB) intended for therapeutic use stipulate that the electronic data management system must be secure, efficient, and traceable. In this context, Research Electronic Data Capture (REDCap) is an electronic data management system originally developed for the collection and management of data in clinical studies, offering a set of integrated functionalities. Objective: To describe the implementation and validation of REDCap as an electronic data management system in an HTB. Methodology: This is a descriptive validation study. Based on the criteria established by current legislation, a validation plan was developed to analyze the important functionalities aimed at ensuring the security and integrity of the data. The functions analyzed were (a) system access and user registration; (b) data export and backup; (c) report generation; (d) traceability; and (e) blocking against alterations. Results: During validation, it was possible to verify that the system has important access control mechanisms, activity logging, and providing complete traceability of entered and modified information. Furthermore, REDCap offers multiple export and backup options, ensuring continued access to information in contingency situations or operational failures. Conclusion: REDCap demonstrated satisfactory compliance with the security, integrity, and traceability criteria required by current regulations for HTBs. Moreover, its replicability may represent a viable alternative for managing electronic data in other healthcare services.

31 August 2026 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
LFLuiz Henrique de Freitas Filho
Luiz Henrique de Freitas Filho
CNCristina de Carvalho Silva Neves
Cristina de Carvalho Silva Neves
GMGustavo Bregalda Mattos
Gustavo Bregalda Mattos
PRPetrus de Paula Ribeiro
Petrus de Paula Ribeiro
HHHelga Caputo Nunes Holzhausen
Helga Caputo Nunes Holzhausen
GCGustavo Constantino de Campos
Gustavo Constantino de Campos
Introdução: As normativas que regulamentam as boas práticas em Bancos de Tecidos Humanos (BTH) destinados ao uso terapêutico determinam que o sistema de gerenciamento dos dados eletrônicos seja seguro, eficiente e rastreável. Nesse contexto, o Research Electronic Data Capture (REDCap) é um sistema de gerenciamento de dados eletrônicos originalmente desenvolvido para a coleta e gestão de dados em estudos clínicos que oferece um conjunto de funcionalidades integradas. Objetivo: Descrever a implementação e validação do REDCap como sistema de gerenciamento de dados eletrônicos em um BTH. Metodologia: Trata-se de um estudo descritivo de validação. Com base nos critérios estabelecidos pela legislação vigente, foi desenvolvido um plano de validação para analisar as funcionalidades importantes que visam garantir a segurança e a integralidade dos dados. Foram analisadas as funções para (a) acesso ao sistema e cadastro de usuário; (b) exportação e backup de dados; (c) elaboração de relatórios; (d) rastreabilidade; e (e) bloqueio contra alterações. Resultados: Durante a validação, foi possível verificar que o sistema possui mecanismos importantes de controle de acesso, registro de atividades, além de permitir total rastreabilidade das informações inseridas e alteradas. Além disso, o REDCap dispõe de múltiplas opções de exportação e backup, o que garante continuidade do acesso às informações em situações de contingência ou falhas operacionais. Conclusão: O REDCap demonstrou atender de forma satisfatória aos critérios de segurança, integridade e rastreabilidade exigidos pelas normativas vigentes aos BTH. Ademais, sua replicabilidade pode ser uma alternativa viável para o gerenciamento de dados eletrônicos em outros serviços de saúde.